• 010-65960098
    ×

    Founded in June 2018, Juventas Cell Therapy Ltd. is a biomedical enterprise focusing on the R&D and commercialization of innovative drugs such as immune cell therapy, which has in-depth cooperation with national first-class institutes and clinical research centers and is committed to building a leading platform for clinical transformation and commercialization of cell therapy, accelerating cell therapy innovation, clinical application and industrialization. Juventas creates safe, efficient and accessible immune cell therapy products for patients through strict product production and quality systems. CNCT19, the first product with Chinese independent intellectual property rights, has obtained two new drug clinical trial licenses from the National Medical Products Administration (NMPA), and is used to treat relapsed or refractory acute lymphoblastic leukemia and relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Recruitment of clinical trial subjects is currently underway to accelerate the listing process and benefit Chinese patients with hematological tumors. Meanwhile, the company continues to build highly scalable and competitive innovation pipelines, covering hematologic tumor pipelines, solid tumor pipelines and forward-looking general platform pipelines. In addition, the company has a world-class R&D platform, process development platform, quality control system and commercial production base. The company has a 2000 square metres R&D center in Beijing, and a nearly 10,000 square metres production base in Tianjin for R&D, transformation and commercialization of immune cell drugs that meets GMP standards.

    Products
    Products

    Juventas CNCT19 is a CAR-T cell therapy product targeting CD19 with independent intellectual property rights. It is used to treat relapsed or refractory acute lymphoblastic leukemia and relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. IND approvals for two indications were obtained on Nov. 29, 2019.

    ×
    R&D Progress
    R&D Progress
    • 2020-12-24
      Investigator Meeting of registered clinical study (CNCT19 NHL) phase II was held in Hangzhou.
    • 2020-12-24
      The registered clinical study (CNCT19 NHL) completed the inspection of the primary endpoint in phase I by independent data monitoring committee.
    • 2020-12-24
      The first subject in the registered Phase I clinical study of CNCT19 successfully achieved cell infusion.
    ×
    Clinical Research
    Clinical Research

    Clinical development abilities and scalable pipeline layout demonstrate the vitality of an excellent biomedical company. Juventas develops by technological innovation covering blood and solid tumors to meet clinical demands and accelerate industrialization.

    ×
    News  |  Events  |  Videos
    我们的目标 Focus on Cell Therapy, Lead a Healthy Future.
    ×
    合源生物CNCT19相关管线
    平台 项目 适应症 临床前研究
    血液肿瘤 CD19 CAR-T (CNCT19) B-ALL 2019.11.29 IND, 2020.01.15 受试者入组
    合源生物CNCT19 (CD19 CAR-T)相关临床试验列表
    登记号 方案标题 网址
    CTR20192701 CNCT19细胞注射液治疗CD19阳性的复发或难治性急性淋巴细胞白血病的l期临床试验 http://www.chinablood.com.cn/system/2019/05/21/014 330776.shtml
    NCT04230473 CNCT19细胞注射液治疗CD19阳性的复发或难治性急性淋巴细胞白血病的l期临床试验 https://clinicaltrials.gov/ct2/show/NCT04230473?term= NCT042304
    ×
    CNCT19 研发历程
    • 2020年3月4日 CNCT19首例受试者成功回输
    • 2020年3月4日 CNCT19首例受试者成功回输
    • 2020年3月4日 CNCT19首例受试者成功回输
    • 2020年3月4日 CNCT19首例受试者成功回输
    • 2020年3月4日 CNCT19首例受试者成功回输
    ×
    CNCT19产品介绍
    合源生物CNCT19细胞注射液是具有自主知识产权的针对CD19靶点的CAR-T细胞治疗产品,源自中国医学科学院血液病医院(血液学研究所)长期技术创新积累。CNCT19细胞注射液于2019年11月29日获得两项国家药品监督管理局新药临床试验许可,分别为治疗复发或难治性急性淋巴细胞白血病的临床试验(受理号:CXSL1800106)和治疗复发或难治性侵袭性B细胞非霍奇金淋巴瘤的临床试验(受理号:CXSL1800107)。此次启动会的举行,标志着中国自主知识产权的CAR-T 细胞治疗产品正式开展注册临床试验并进行受试者招募,在临床转化和产业化发展道路上又迈出了关键一步,合源生物将加速推进CNCT19细胞注射液临床研究进程,早日惠及患者。
    官方彩票网站